INTELLIA THERAPEUTICS INC (NTLA) — insider trading
Health Care · NASDAQ
INTELLIA THERAPEUTICS INC (NTLA) has 27 reported SEC Form 4 insider transactions in our data, including 7 open-market sales among the most recent 27 (latest 2026-10-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Dube Michael P | Officer (VP, Chief Accounting Officer) | Open-market sale | 1,864 | $12.43 | $23.2K | Form 4 |
| 2026-08-21 | LEONARD JOHN M | Director, Officer (President and CEO) | Open-market sale | 2,785 | $13.00 | $36.2K | Form 4 |
| 2026-08-20 | LEONARD JOHN M | Director, Officer (President and CEO) | Open-market sale | 19,890 | $12.60 | $250.6K | Form 4 |
| 2026-07-22 | Dulac Edward J III | Officer (EVP, Chief Financial Officer) | Open-market sale | 8,111 | $11.25 | $91.2K | Form 4 |
| 2026-07-02 | Dulac Edward J III | Officer (EVP, Chief Financial Officer) | Open-market sale | 4,677 | $18.00 | $84.2K | Form 4 |
| 2026-07-01 | Dube Michael P | Officer (VP, Chief Accounting Officer) | Open-market sale | 2,641 | $16.78 | $44.3K | Form 4 |
| 2026-06-09 | Bhanji Muna | Director | Grant / award / vesting (derivative) | 13,300 | — | $0 | Form 4 |
| 2026-06-09 | Bhanji Muna | Director | Grant / award / vesting | 9,200 | — | $0 | Form 4 |
| 2026-06-09 | CHASE WILLIAM J | Director | Grant / award / vesting (derivative) | 13,300 | — | $0 | Form 4 |
| 2026-06-09 | CHASE WILLIAM J | Director | Grant / award / vesting | 9,200 | — | $0 | Form 4 |
| 2026-06-09 | Cohen Fred E | Director | Grant / award / vesting (derivative) | 13,300 | — | $0 | Form 4 |
| 2026-06-09 | Cohen Fred E | Director | Grant / award / vesting | 9,200 | — | $0 | Form 4 |
| 2026-06-09 | Goff Brian | Director | Grant / award / vesting (derivative) | 13,300 | — | $0 | Form 4 |
| 2026-06-09 | Goff Brian | Director | Grant / award / vesting | 9,200 | — | $0 | Form 4 |
| 2026-06-09 | GOODMAN JESSE | Director | Grant / award / vesting (derivative) | 13,300 | — | $0 | Form 4 |
| 2026-06-09 | GOODMAN JESSE | Director | Grant / award / vesting | 9,200 | — | $0 | Form 4 |
| 2026-06-09 | Keresty Georgia | Director | Grant / award / vesting (derivative) | 13,300 | — | $0 | Form 4 |
| 2026-06-09 | Keresty Georgia | Director | Grant / award / vesting | 9,200 | — | $0 | Form 4 |
| 2026-06-09 | Verwiel Frank | Director | Grant / award / vesting (derivative) | 13,300 | — | $0 | Form 4 |
| 2026-06-09 | Verwiel Frank | Director | Grant / award / vesting | 9,200 | — | $0 | Form 4 |
| 2026-03-02 | BASTA JAMES | Officer (EVP, General Counsel) | Open-market sale | 1,211 | $13.78 | $16.7K | Form 4 |
| 2026-03-01 | Lebwohl David | Officer (EVP, Chief Medical Officer) | Grant / award / vesting (derivative) | 14,204 | — | $0 | Form 4 |
| 2026-03-01 | Lebwohl David | Officer (EVP, Chief Medical Officer) | Grant / award / vesting | 9,943 | — | $0 | Form 4 |
| 2026-03-01 | BASTA JAMES | Officer (EVP, General Counsel) | Grant / award / vesting (derivative) | 65,829 | — | $0 | Form 4 |
| 2026-03-01 | BASTA JAMES | Officer (EVP, General Counsel) | Grant / award / vesting | 46,080 | — | $0 | Form 4 |
| 2026-03-01 | LEONARD JOHN M | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 225,400 | — | $0 | Form 4 |
| 2026-03-01 | LEONARD JOHN M | Director, Officer (President and CEO) | Grant / award / vesting | 156,400 | — | $0 | Form 4 |
Ask the chat about NTLA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: INTELLIA THERAPEUTICS INC (NTLA).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.